Tigecycline
- PDF / 169,338 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 115 Downloads / 157 Views
1 S
Increased amylase level, nausea and lethargy: 2 case reports In a single-centre, retrospective observational study conducted between January 2016 and June 2018 involving patients treated with tigecycline as outpatient parenteral antibiotic therapy (OPAT), two patients [ages and sexes not stated] were described, who experienced nausea (one patient) or had increased amylase level, nausea and lethargy (one patient) during treatment with tigecycline [dosage and duration of treatment to reactions onsets not stated; not all outcomes stated]. Case 1: The patient, who had been receiving tigecycline IV infusion daily at a rate of 30 min, experienced nausea during treatment. The nausea improved on slower IV administration of tigecycline (60 min rather than 30 min). Case 2: The patient, who had been receiving tigecycline IV infusion daily, showed increased amylase level (up to 190 IU/L) in the week 1 of the tigecycline treatment. Tigecycline was continued. During follow-up at week 2, the patient showed improvement in amylase level (156 IU/L). Furthermore, treatment with tigecycline was discontinued due to nausea and lethargy. Hughes S, et al. Once-daily tigecycline for outpatient parenteral antibiotic therapy: A single-centre observational study. JAC-Antimicrobial Resistance 1: No. 3, 24 Dec 2019. 803518122 Available from: URL: http://doi.org/10.1093/jacamr/dlz085
0114-9954/20/1832-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 28 Nov 2020 No. 1832
Data Loading...
